Delayed-onset ticlopidine-induced cholestatic jaundice.
An 86-year-old man experienced a rash approximately 2 weeks after starting ticlopidine therapy, necessitating discontinuation of the drug. About 1 month later, despite discontinuation, he developed jaundice and liver test abnormalities. These resolved gradually over the next few months. Based on case reports and the drug's pharmacokinetic profile, a high index of suspicion for ticlopidine-induced jaundice is prudent in patients with recent exposure to the agent who have evidence of liver damage.
Kubin
C J
CJ
Department of Pharmacy, Bronx VA Medical Center, New York 10468, USA.
Sherman
O
O
Hussain
K B
KB
Feinman
L
L
D000368:Aged; D056486:Chemical and Drug Induced Liver Injury; D002779:Cholestasis / Q000139:chemically induced*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D013988:Ticlopidine / Q000009:adverse effects*; D013997:Time Factors
D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine